The April 2026 move of state-licensed medical cannabis to Schedule III was a landmark, but it was not the end of the story. In late June 2026, expedited federal hearings began on broader rescheduling questions, examining whether cannabis policy should shift further. Here is a plain-language look at what is happening and what it could mean.
Since April 28, 2026, state-licensed medical cannabis has been classified under Schedule III, which recognizes accepted medical use. Our Schedule III guide covers what that change did and did not do. State law still governs patient access, and only DCC-licensed operators may sell or deliver cannabis in California.
The expedited proceedings that commenced in late June 2026 are examining broader rescheduling questions beyond the April change. Hearings like these gather testimony and evidence on accepted medical use, abuse potential, and public health data, and they typically run for months before any recommendation or ruling is issued.
Practically, nothing changes today. Your access is governed by California law, your recommendation or adult medicinal status is verified the same way, and licensed operators keep operating under DCC rules. The value of watching these hearings is knowing where the ground may move: further normalization would likely mean more research, more physician engagement, and more stable patient services over time.
ThrivePath was built compliance-first for exactly this environment. Our founders spent a decade working on cannabis policy in Long Beach, from the 2012 ban through Measure MM in 2016, and we track every federal development so our patients never have to guess. When the hearings produce real outcomes, we will explain them here in plain language.
ThrivePath Medical is preparing to launch delivery for qualified patients across Long Beach and surrounding areas.
Check if we deliver to you